ImmunoPrecise Antibodies Overview
- Founded
-
1989
- Status
-
Public
- Employees
-
73
- Stock Symbol
-
IPA
- Investments
-
8
- Share Price
-
$3.79
- (As of Thursday Closing)
ImmunoPrecise Antibodies General Information
Description
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from the United States of America.
Contact Information
Primary Industry
Biotechnology
Stock Exchange
TSX
Primary Office
- Vancouver Island Technology Park Unit
- 3204-4464 Markham Street
- Victoria, British Columbia V8Z 7X8
- Canada
+1 (250) 000-0000
ImmunoPrecise Antibodies Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.79 | $3.73 | $3.55 - $16.07 | $87.7M | 23.5M | 15.4K | -$0.73 |
ImmunoPrecise Antibodies Financials Summary
|
In Thousands, USD |
TTM 31-Jan-2022 | FY 2021 30-Apr-2021 | FY 2020 30-Apr-2020 | FY 2019 30-Apr-2019 |
|---|---|---|---|---|
| EV | 91,389 | 179,074 | 40,099 | 35,706 |
| Revenue | 15,162 | 13,667 | 10,522 | 8,291 |
| EBITDA | (8,897) | (1,298) | (375) | (3,082) |
| Net Income | (13,642) | (5,600) | (3,703) | (5,780) |
| Total Assets | 44,234 | 54,539 | 19,647 | 21,152 |
| Total Debt | 2,205 | 2,816 | 3,249 | 2,175 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ImmunoPrecise Antibodies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ImmunoPrecise Antibodies Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The c
Biotechnology
Victoria, Canada
73
As of 2021
000.00
00000000
000.00
000000
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
0000000000000
Planegg, Germany
00
As of 0000
00000
000000000
00000
000000
ate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
0000000000000
Shirley, NY
Add Comparison
ImmunoPrecise Antibodies Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MediGene | Formerly VC-backed | Planegg, Germany | 00 | 00000 | 000000000 | 00000 |
| 00000000 000000000 | Corporation | Shirley, NY | ||||
| 000000000 | Private Equity-Backed | Piscataway, NJ | 0000 | 00000 | 000000000 | 00000 |
ImmunoPrecise Antibodies Patents
ImmunoPrecise Antibodies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2947722-A1 | Monoclonal antibodies for the identification and characterization of antiestrogens and selective estrogen receptor modulators | Abandoned | 04-Nov-2016 | 00000000000 | |
| CA-2947878-A1 | Monoclonal antibodies and use thereof as a diagnostic tool for limb-girdle muscular dystrophy | Pending | 04-Nov-2016 | 000000000 | |
| CA-2964907-A1 | Monoclonal antibodies and use thereof as a diagnostic tool for limb-girdle muscular dystrophy and genetically related disorders | Pending | 04-Nov-2016 | 000000000 | |
| CA-2965017-A1 | Monoclonal antibodies for the identification and characterization of antiestrogens and selective estrogen receptor modulators | Pending | 04-Nov-2016 | 00000000000 | |
| CA-2940065-A1 | Method for the rapid production of high affinity monoclonal anitibodies | Pending | 22-Aug-2016 | C07K16/00 |
ImmunoPrecise Antibodies Executive Team (11)
ImmunoPrecise Antibodies Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 000000000 | ImmunoPrecise Antibodies | Board Member | 000 0000 |
| 0000 00000 | Self | Board Member | 000 0000 |
| 00000 000 00 | Self | Chairman & Board Member | 000 0000 |
| 00000000 0000 00.0 | ImmunoPrecise Antibodies | Chief Executive Officer & Board Member | 000 0000 |
| 0000 00000000 | Self | Board Member | 000 0000 |
ImmunoPrecise Antibodies Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ImmunoPrecise Antibodies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ImmunoPrecise Antibodies Investments & Acquisitions (8)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 (00 | 29-Mar-2022 | 0000000000 | 0000 | Other Healthcare Technology Systems | 00000000 |
| 000000000 000 | 06-Apr-2018 | 0000000000 | 00.000 | Discovery Tools (Healthcare) | |
| 000000000 000 | 30-Jan-2018 | 0000000000 | 000.00 | Drug Discovery | |
| 0000000 | 29-Dec-2017 | 000000000 | 00000 | Discovery Tools (Healthcare) | |
| Preclinics | 28-Dec-2017 | Merger/Acquisition | 00.000 | Other Services (B2C Non-Financial) |
ImmunoPrecise Antibodies Subsidiaries (4)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Preclinics | Other Services (B2C Non-Financial) | Potsdam, Germany | 2007 |
| 0-0000000 0000000 | Biotechnology | Utrecht, Netherlands | 0000 |
| 000000000 00000000 | Drug Discovery | Utrecht, Netherlands | 0000 |
| 000 00000000 | Biotechnology | Utrecht, Netherlands |
ImmunoPrecise Antibodies Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 | 29-Dec-2017 | 000000000 | 00000 | Completed |
|